Kezar Life Sciences, Inc. (KZR)
NGM · Healthcare · Biotechnology
$7.29
Closing price as of 2026-05-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$53.9M
Shares Outstanding
7.4M
Exchange
NGM
Currency
USD
About Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (17.6M) | (14.6M) | (11.7M) | (8.3M) |
| Net Income | (16.6M) | (13.7M) | (11.2M) | (14.5M) |
| Diluted EPS | $-2.00 | $-1.87 | $-1.53 | N/A |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 7.0M | 0.00 | 0.00 |
| Operating Income | (71.2M) | (105.2M) | (89.1M) | (52.3M) |
| Net Income | (68.2M) | (101.9M) | (83.7M) | (56.0M) |
| Diluted EPS | $-10.10 | $-14.04 | $-11.00 | $-7.66 |